Mesh nebulizers are now an important delivery system for the treatment of high-value drugs in diseases such as cystic fibrosis and pulmonary hypertension where alternate delivery systems such as metered dose inhalers (MDIs) and dry powder inhalers (DPIs) have not been popular due to the higher cost of developing these devices and the limited mass of drug that can be delivered in a single inhalation. However, in the asthma and COPD markets where MDIs and DPIs are often the delivery system of choice, nebulizer use has been limited to patient groups such as the young and elderly who may be unable to use an MDI